Effect of osimertinib in ethnic Chinese with EGFR and T790M mutated NSCLC
Study identifier:D5160R00016
ClinicalTrials.gov identifier:NCT03133234
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Observational, Retrospective, Real World Study of osimertinib in Ethnic Chinese Patients with Locally advanced/Metastatic T790M Mutation-Positive non-small-cell lung cancer (NSCLC )progressed on previous epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
Medical condition
T790M positive NSCLC patients
Phase
N/A
Healthy volunteers
No
Study drug
osimertinib
Sex
All
Actual Enrollment
47
Study type
Observational
Age
18 Years +
Date
Study Start Date: 23 May 2017
Primary Completion Date: 13 Sept 2017
Study Completion Date: 13 Sept 2017
Study design
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: -
Verification:
Verified 01 Nov 2018 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| EGFR T790M Patients Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI | Drug: osimertinib Oral dose of 80mg once daily Other Name: NA |
Contacts
Investigators
Principal Investigator
Yabing Cao
Kiang Wu Hospital
